Gene Therapy Enjoys Bulk of Intracranial Therapeutic Delivery Market Share at Over 80%: Persistence Market Research

Published On : Aug 03, 2022

The global intracranial therapeutic delivery market is currently valued at around US$ 1.6 Bn and is anticipated to progress at an impressive CAGR of 7.9% over the 2022-2032 study period.

Cell and gene therapies are at the forefront of innovation in treating severe diseases, such as cancer, as well as rare diseases, accounting for around 12 percent of the pharmaceutical industry’s clinical pipeline. However, the growing focus on effective therapy has impacted positive financial grades for cell and gene therapy throughout the clinical and social spectrum; intracranial therapeutic administration has been gaining favor in the biopharma industry.

The progressive development of CRISPR and next-generation sequencing has led to a surge in the interest in gene therapy and cell treatment in the past few years. The manufacturing community for cell and gene therapies, including pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and suppliers of lab supplies and equipment, are looking into ways to strengthen supply chains and address process bottlenecks.

Sales footprint expansion, which has been gaining more and more traction among key participants, calls for the desired assistance, based on financial approvals and consolidated activities. Additionally, several clinical trials have been carried out in association with research institutes.

  • For instance, to determine the safety and effectiveness of gene therapy deliver a crucial protein into the brains of patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI), a condition that frequently precedes dementia, researchers at the University of California San Diego School of Medicine have started a first-in-human phase I clinical trial.

Key Takeaways from Market Study

  • Gene therapy accounted for the highest market share of 81.9% in terms of source in 2021.
  • Spinal Muscular Atrophy (SMA) contributed nearly 81.9% of the market share in 2021 and is expected to dominate throughout the forecast period (2022-2032).
  • Rest of the world is the leading regional market got intracranial therapeutic delivery, holding 41.8% share in 2021.

“Rising prevalence of neurological disorders and increasing research activities for the development of regenerative medicine to drive market growth over the coming years,” says an analyst of Persistence Market Research.

View Report Table of Contents, Figures, and Tables

Market Competition

The therapeutic delivery for intracranial is a highly consolidated market with limited key manufacturers operating in the industry. A majority of market players are focused on offering a limited range of cell, gene, and enzyme replacement therapy used for neurological disorder indications.

To strengthen their position in the global market, key players are focusing on strategic approaches such as mergers and collaborations to improve their production capabilities and expand their portfolios in various clinical and research fields.

For Instance,

  • In April 2022, LabCorp and Xcell Biosciences, Inc. advanced vital work that enables clients to successfully commercialize cutting-edge cell and gene therapies. Through an agreement for cooperation, the companies collaborated on a number of initiatives aimed at enhancing the security and effectiveness of cell and gene therapies.
  • In September 2021, A Roche Group member of Spark Therapeutics and NeuExcell Therapeutics entered into a collaborative agreement to develop an efficacious treatment line for treating Huntington's disease (HD) patients.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the intracranial therapeutic delivery market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the therapy (cell-based therapy, gene therapy, and enzyme replacement therapy) and indication (spinal muscular atrophy (SMA), multiple sclerosis, batten disease), and amyotrophic lateral sclerosis, across three key regions of the world considered in the taxonomy.

For additional insights on how the growth of the intracranial therapeutic delivery market will unfold over the decade, write to the analyst at

Persistence Market Research’s Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.

Intracranial Therapeutic Delivery Market

Market Study on Intracranial Therapeutic Delivery: Industry Benefiting from Rising Neurological Disorder Prevalence and Tangible Shift toward Regenerative Medicines

Intracranial Therapeutic Delivery Market